Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
The growth of the minimal residual disease testing goes up to USD 6.38 billion by 2032. This is at a CAGR of 11.36% from 2032 to 2032 3. This indicates that there will be a lot of money involved with it. The Minimal Residual Disease (MRD) Testing Market envelopes an area being governed by several parameters that together hold the core of its development and expansion. MRD testing is a technologically advanced method of detection and assessment of microscopic quantities of residual cancer cells in the human body, which may persist after treatment. The market factors have a considerable impact on the market through the improvements in molecular diagnostics, increasing incidence of cancer, emphasizing on personalized medicine with regards to to the regulatory considerations and trying to get more sensitive and accurate detection inventions.
The Molecular Diagnostics field in general is one of the key factors that are transforming the situation in the MRD testing market greatly. With the high-throughput sequencing technology, next-generation sequencing (NGS) and the frequent and unique molecular assays, the sensitivity and specificity of minimal residual disease (MRD) testing is much higher now than previously.
The rising occurrence of cancer worldwide is a main motivator that is fuelling the market trends of liquids having monoclonal antibodies. Cancer incidence is on the rise coupled with the growing demand of better treatment approaches. Monitoring cancer if still present or showing signs of recurrence becomes critical in treatment response evaluation and patient's prognosis. The ascendancy of the MRD testing, which has been proven to be feasible in various cancer types like hematological malignancies and solid tumors, portends the fast-paced nature of the market in quest of the best results for patients that are possible using early and accurate detection.
Modern approaches in personalized medicine is now an important factor in changing the market landscape of MRD testing. Customized treatment strategies, designed to fit individual genomic and molecular profiles of particularly patient, always need diagnostic details offered by MRD testing for perfection. MRD testing integration is leading to that of personalized medicine for patients and the consequent market dynamics interference. The effects on cancer care are beyond the comprehension of many.
Another major driving force that compete diagnostic companies and the testing laboratories offering MRD testing service is the market competition. Firms endeavor to distinguish themselves from competitors by inventing unique MRD testing platforms applicable to broader spectrum of cancer types, as well as they are enhancing the time needed for results. The highly competitive market culture accommodates innovativeness as entities strive to fill range needs of oncologists, to improve the reach of MRD testing, and to better patients' experiences. This competition unleashes the continuous evolution of the MRD Testing Market with the constant urge to reach newer heights in technology and meet the requirements of the cancer research fraternity.
Covered Aspects:
| Report Attribute/Metric | Details |
|---|---|
| Growth Rate | 11.36% (2023-2032) |
Minimal Residual Disease Testing Market Highlights:
Global Minimal Residual Disease Testing Market Overview
The Minimal Residual Disease Testing Market size was valued at USD 1.92 billion in 2022 and is projected to grow from USD 2.17 billion in 2023 to USD 6.38 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 11.36% during the forecast period (2023 - 2032).
The factors that are influencing the growth of the market are the increasing incidence of hematological malignancies and rising cancer awareness initiatives by global health organizations.
FIGURE 1: MINIMAL RESIDUAL DISEASE TESTING MARKET, 2022 to 2032 (USD BILLION)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Minimal Residual Disease Testing Market Trends
- Increasing incidence of hematological malignancies
The incidence of hematological malignancies, which are cancers of the blood and bone marrow, has been increasing globally over the past few decades. This increase is thought to be due to a combination of factors, including an aging population, a change in lifestyle, and a rising number of people with weakened immune systems. Moreover, according to GLOBOCAN 2020, new cases for leukemia were 474,519, non-Hodgkin lymphoma cases were 544,352, and Hodgkin cases were 83,087. Furthermore, initiatives are having a positive impact on cancer awareness and prevention. Global health organizations such as the World Health Organization (WHO), the Union for International Cancer Control (UICC), the World Cancer Research Fund International, and Worldwide Cancer Research are committed to continuing to raise cancer awareness and reduce the burden of cancer worldwide. Moreover, initiatives undertaken include providing information and education about cancer, supporting cancer research, advocating for cancer control policies, and empowering cancer survivors.
Therefore, rising incidences of minimal residual disease testing and growing awareness through global organization are fueling the growth of the market.
Minimal Residual Disease Testing Market Segment Insights
Minimal Residual Disease Testing Market Technology Insights
The Minimal Residual Disease Testing Market is segmented, based on technology, into flow cytometry, polymerase chain reaction (PCR), next-generation sequencing (NGS), and others. The flow cytometry segment held the majority share of the market and next-generation sequencing (NGS) is the fastest-growing segment during the forecast year. The widely preferred technique for minimal residual disease testing is flow cytometry and NGS. The flow cytometry approach can find one cancer cell among 100,000 bone marrow cells and provide results that can be available in less than one day. Moreover, PCR tests provide advantages such as high sensitivity, specificity, reproducibility, and rapid turnaround time.
Thus, the above-mentioned technologies are widely preferred for hematological malignancies and provide immense advantages for diagnosing cancer, fostering the growth of the technology segment.
Minimal Residual Disease Testing Market Application Insights
The Minimal Residual Disease Testing Market segmentation, based on application, includes lymphoma, leukemia, solid tumors, and others. The leukemia segment dominated the market in the base year, i.e., 2022, and lymphoma is the fastest-growing segment during the forecast period, 2023–2032. This is due to the rising incidence of both leukemia and lymphoma cases across the globe. Moreover, the rapid launch of minimal residual tests for leukemia is also boosting the growth of the segment. For instance, in October 2021, Sysmex Inostics, Inc. (US) launched a clinically validated liquid biopsy test for the detection of minimal residual disease (MRD) for acute myeloid leukemia (AML). This test is based on next-generation sequencing.
Therefore, the increasing incidences of hematological malignancies and the launch of innovative MRD testing that targets the NGS panel are positively impacting the growth of the market.
FIGURE 2: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2022 & 2032 (USD BILLION)
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
Minimal Residual Disease Testing Market End User Insights
Based on end user, the Minimal Residual Disease Testing Market has been segmented into hospitals & clinics, diagnostic laboratories, and others. The hospital & clinics segment dominated the market in 2022, and the diagnostic laboratories segment is the fastest-growing segment during the forecast period, 2023–2032. This is due to the rapid adoption of newly launched MRD tests at diagnostic centers as well as the frequent adoption of MSD tests by patients. Moreover, MRD tests are being popularized due to their immense benefits in diagnosing cancer. Furthermore, as per the research, MRD is being utilized by hospitals and clinics to monitor the effectiveness of cancer treatment and detect cancer recurrence early.
Minimal Residual Disease Testing Market Regional Insights
By region, the study segments the market into North America, Europe, Asia-Pacific, and the Rest of the World. In North America, the minimal residual disease testing market held the largest market share in 2022 due to the presence of major players in the US such as Adaptive Biotechnologies (US), Sysmex Inostics, Inc. (US), Arup Laboratories Inc. (US), ArcherDX, Inc. (US), and Asuragen Inc. (US). Additionally, the rising incidences of lymphoma and leukemia are driving the growth of the North America region. As per the American Cancer Society's estimated that there were 59,610 new cases of leukemia and 23,710 deaths from leukemia in the US in 2023. Further, 20,380 cases of acute myeloid leukemia were reported in 2023.
Hence, the presence of major players in the region and increasing incidences of cancer are fostering the growth of the North American minimal residual disease testing market.
Further, the major countries studied are: The US, Canada, France, Germany, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
FIGURE 3: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY REGION, 2022 & 2032 (USD BILLION)
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
The European minimal residual disease testing market accounted for the second-largest market share due to the growing geriatric population. The incidences of blood related cancers increase with increases in age. The risk of leukemia is more than 10 times higher in people over the age of 65 than in people under the age of 45. In September 2022, it has been estimated by the World Economic Forum that more than 30% of the European population are expected to be 65 or older by 2100. Thus, growing geriatric population will create greater opportunities for the Europe market during the forecast period. Moreover, the Germany minimal residual disease testing market held the largest market in 2022, and the France minimal residual disease testing market is projected to be the fastest-growing market in the Europe region.
The Asia-Pacific minimal residual disease testing market is the fastest growing region from 2023 to 2032, owing to the growing incidence of hematological cancer, increased geriatric population, and the strategic formation to meet the demand of customers boosts Asia-Pacific region growth. For instance, October 2021, Genetron Health (China) and Jiangsu Fosun (China) started commercialization of MRD detection test in China, also promoted Seq-MRD in hematologic-focused hospitals and clinics in China. This test provides accuracy, high throughput, cost-efficiency, uniformity and fast turnaround time. Furthermore, the China minimal residual disease testing market accounted for the largest market share in 2022, and the India minimal residual disease testing market is projected to be the fastest-growing market in the Asia-Pacific region.
Minimal Residual Disease Testing Market Key Market Players & Competitive Insights
The key players in the Minimal Residual Disease Testing Market are investing heavily in research and development in order to develop new and more sensitive MRD testing technologies. They are also expanding their geographic reach through product launches, contractual agreements, mergers & acquisitions, investments, and collaboration with other market players in order to make MRD testing more accessible to patients around the world.
Adaptive Biotechnologies (US) is a clinical-stage company that develops next-generation immunosequencing (NGS) platforms and products to help physicians diagnose, treat, and monitor patients with cancer and other diseases. The company has a wide range of locations in North America and Europe. Furthermore, in October 2022, Adaptive Biotechnologies (US) partnered with Epic Systems Corporation in order to integrate the clonoSEQ assay into Epic’s comprehensive electronic medical record (EMR) system. The clonoSEQ Assay has been monitored by the US Food and Drug Administration and approved for chronic lymphocytic leukemia (CLL), multiple myeloma (MM), and B-cell acute lymphoblastic leukemia (ALL) to detect minimal residual disease.
Key Companies in the Minimal Residual Disease Testing Market are included.
- Adaptive Biotechnologies (US)
- Sysmex Inostics, Inc. (US)
- Arup Laboratories Inc. (US)
- ArcherDX, Inc. (US)
- Asuragen Inc. (US)
- Bio-Rad Laboratories, Inc. (US)
- Guardant Health (US)
- QIAGEN N.V. (Germany)
- FOUNDATION MEDICINE, INC. (US)
- GRAIL, Inc. (US)
Minimal Residual Disease Testing Market Industry Developments
- October 2021: Sysmex Inostics, Inc. (US) launched a clinically validated liquid biopsy test for the detection of minimal residual disease (MRD) for acute myeloid leukemia (AML). This test is based on next-generation sequencing.
- June 2020: ArcherDX, Inc. (US) collaborated with Bristol Myers Squibb (US) to investigate the potential benefits of minimal residual disease (MRD) identification in cancer patients receiving immunotherapy using personalized cancer monitoring (PCMTM) tests.
Minimal Residual Disease Testing Market Segmentation
Minimal Residual Disease Testing Market Technology Outlook
- Flow Cytometry
- Polymerase Chain Reaction (PCR)
- Next-generation Sequencing (NGS)
- Others
Minimal Residual Disease Testing Market Application Outlook
- Lymphoma
- Leukemia
- Solid Tumors
- Others
Minimal Residual Disease Testing Market End User Outlook
- Hospitals & Clinics
- Diagnostic Laboratories
- Others
Minimal Residual Disease Testing Market Regional Outlook
- North America
- US
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
- Rest of the World
- Middle East
- Africa
- Latin America
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
